Repository series · ncbi-prjna639313
Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants
Immune checkpoint inhibitors (ICIs) is yet to have a major advantage over conventional therapies, as only a fraction of patients benefit from the currently approved ICIs and the response rates remain low. We investigated the effects of different ICIs, anti-PD-1, anti-PD-L1 and anti-TIM-3, on human primary breast cancer explant cultures using RNA-Seq.
The accession and its GCC connection are verified. Registration alone does not establish that the broader research programme remains active.
01 / Project overview
What the record establishes.
- Geographic scope
- Qatar connection indexed in BioProject metadata
- Project type
- Repository project
- Research domain
- Human health and population genomics
- Years
- 2020–
- Lifecycle status
- repository_recorded
- Status basis
- Registered in NCBI BioProject on 2020/06/14; operational lifecycle is not asserted.
- Status evidence date
- 2020-06-14
- Scale
- 1 BioProject accession grouped by matching submitter, date, data type and narrative.
02 / Organizations and population
Who and what the project connects.
- Lead organizations
- Qatar Biomedical Research Institute
- Partner organizations
- Not stated
- Organism / population
- Not stated
03 / Data and access
What exists and how it can be reached.
Data types
- Raw sequence reads
- Sequencing
- Genome
Data access
Public repository metadata with linked data where supplied by the submitter
Identifiers
- BioProject
PRJNA639313
04 / Evidence and provenance
Why the record is included.
Inclusion basis
Exact country-name match in authoritative NCBI BioProject metadata; repeated submissions are grouped into one Atlas series.
Editorial note
Repository verification confirms the accession and regional connection, not whether the broader research programme remains active.
Sources
- primary record source Verified 2026-08-15
Release v0.2.0